Simple and rapid monitoring of doxorubicin using streptavidin-modified microparticle-based time-resolved fluorescence immunoassay

Liang, Junyu; Zhang, Zhigao; Zhao, Hui; Wan, Shanhe; Zhai, Xiang-Ming; Zhou, Jianwei; Liang, Rongliang; Deng, Qiaoting; Wu, Yixuan; Lin, Guanfeng

doi:10.1039/c8ra01807c

Cited by 21 publications

(17 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to literature, DOX has a stable UV absorption wavelength (around 480 nm) and red fluorescence emission of about 590 nm [ 30 ]. Therefore, the ability of DOX-Fe 3 O 4 @agar NPs to release the DOX drug was monitored by UV-vis spectrophotometer.…”

Section: Resultsmentioning

confidence: 99%

Utilizing Edible Agar as a Carrier for Dual Functional Doxorubicin-Fe3O4 Nanotherapy Drugs

et al. 2021

View full text Add to dashboard Cite

The purpose of this study was to use agar as a multifunctional encapsulating material to allow drug and ferromagnetism to be jointly delivered in one nanoparticle. We successfully encapsulated both Fe3O4 and doxorubicin (DOX) with agar as the drug carrier to obtain DOX-Fe3O4@agar. The iron oxide nanoparticles encapsulated in the carrier maintained good saturation of magnetization (41.9 emu/g) and had superparamagnetism. The heating capacity test showed that the specific absorption rate (SAR) value was 18.9 ± 0.5 W/g, indicating that the ferromagnetic nanoparticles encapsulated in the gel still maintained good heating capacity. Moreover, the magnetocaloric temperature could reach 43 °C in a short period of five minutes. In addition, DOX-Fe3O4@agar reached a maximum release rate of 85% ± 3% in 56 min under a neutral pH 7.0 to simulate the intestinal environment. We found using fluorescent microscopy that DOX entered HT-29 human colon cancer cells and reduced cell viability by 66%. When hyperthermia was induced with an auxiliary external magnetic field, cancer cells could be further killed, with a viability of only 15.4%. These results show that agar is an efficient multiple-drug carrier, and allows controlled drug release. Thus, this synergic treatment has potential application value for biopharmaceutical carrier materials.

show abstract

Section: Resultsmentioning

confidence: 99%

Utilizing Edible Agar as a Carrier for Dual Functional Doxorubicin-Fe3O4 Nanotherapy Drugs

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The spectra (Figure 6) showed that Dox emitted a maximum fluorescence signal at approximately 590 nm, which agreed with results in the literature. 57 In addition, its fluorescence was quenched completely upon mixing with CAH, indicating complete intercalation at Dox to CAH molar ratio of 1:5. Dox has two major moieties in its structure: an amino sugar group and a tetracyclic core.…”

Section: Characterization Of Dox-cahmentioning

confidence: 99%

A molecular hybrid comprising AS1411 and PDGF‐BB aptamer, cholesterol, and doxorubicin for inhibiting proliferation of SW480 cells

Rotkrua

Lohlamoh

Watcharapo

et al. 2021

J of Molecular Recognition

View full text Add to dashboard Cite

Cancer treatment commonly relies on chemotherapy. This treatment faces many challenges, including treatment specificity and undesired side effects. To address these, a Dox-loaded Chol-aptamer molecular hybrid (Dox-CAH) was developed. This multivalent interaction system combines the key function of each integrated species: doxorubicin, cholesterol, and two aptamers binding to nucleolin and platelet-derived growth factor BB (PDGF-BB). The study has four stages: preparation of CAH via oligonucleotide hybridization, intercalation of doxorubicin into CAH, verification of CAH binding on SW480 by fluorescence microscopy and flow cytometry, and investigation of effect of Dox-CAH on SW480 proliferation. CAH was successfully prepared, as confirmed by electrophoresis. Flow cytometry and fluorescence microscopy demonstrated CAH binding to SW480, due to the presence of the AS1411 aptamer. This molecular hybrid exhibited specific binding because it did not bind to CCD 841 CoN. CAH binding to PDGF-BB compromises its function, as shown by enzymelinked immunosorbent assay (ELISA) and cell assay. The DNA duplex in this molecular hybrid reduces the cytotoxicity of the Dox-CAH. Binding and the reduction of Dox-CAH toxicity may improve treatment specificity and minimize side effects. Dox-CAH is a model for more effective anticancer therapy, allowing incorporation of chemotherapeutic drugs and recognition elements.

show abstract

“…Using the scanning spectrophotometer we obtained a wavelength of fluorescence emission spectrum at ~580 nm, which is also consistent with previous researches (Chapman et al, 2016) (Fig 5a). We further conducted a linear regression analysis to evaluate the validity and the linearity of the concentration- Doxorubicin excitation wavelength was found at ~483 nm for concentrations range 1 -0.1 µM, which is consistent with previous studies (Liang et al, 2018) (Fig 7a). At the same concentrations, fluorescence emission wavelength was found ~592 nm (Fig 7b).…”

Section: Spectrophotometersupporting

confidence: 87%

Identification of Molecules by Spectral Imaging

Alshammari¹

View full text Add to dashboard Cite

Identification of Molecules by Spectral Imaging by Qamar A. Alshammari Spectral imaging is a powerful technique which uses the wavelength to identify/quantify the exact location and amount of the molecules. It facilitates the identification of materials and studying their properties through analyzing the way they interact with light. The study of light interaction with elements is called spectroscopy; spectroscopy examines how light behaves in the target and recognizes materials based on their spectral signatures. Spectral signatures can be compared to fingerprints which can be used to identify a person; spectral signatures can be used to identify materials. Therefore, we hypothesize that identifying the exact location and quantity of molecules present in the given cells samples can be done by using a spectral imaging system. In this study, we identify the exact UV-Vis and fluorescence spectra of organic substances including Rhodamine 6G, Doxorubicin and UV-Vis spectra inorganic compounds including silver (Ag), gold (Au) nanoparticles (NPs). After that, we used the Q-TOF LC/MS system to quantify the maximum and minimum detectable concentrations of Rhodamine 6G and Doxorubicin by checking the chemicals spectrum based on the molecular weight. In addition, we used HPLC system to quantify the chemicals basing on their UV spectrum. Forwards, we used spectral imaging system to determine the exact amount and location of the molecules within cells samples. For Rhodamine 6G and doxorubicin, we started with the minimum detectable concentration by Q-TOF and consider it as a maximum limit with spectral imaging. And for NPs we used the maximum concentration for the analysis. Using the spectral imaging we were able to vii detect the exact location of Rhodamine 6G which was in the cytoplasm, Doxorubicin in the nucleoplasm, and NPs in both. Furthermore, spectral imaging was able to detect much lower concentrations of Rhodamine 6G and Doxorubicin by the spectrum in comparison to Q-TOF LC/MS. viii

show abstract

Simple and rapid monitoring of doxorubicin using streptavidin-modified microparticle-based time-resolved fluorescence immunoassay

Abstract: Simple, rapid SA-MPs based TRFIA, is applied in therapeutic drug monitoring and the analytical performance is comparable with LC-MS/MS.

Cited by 21 publications

References 42 publications

Utilizing Edible Agar as a Carrier for Dual Functional Doxorubicin-Fe3O4 Nanotherapy Drugs

Utilizing Edible Agar as a Carrier for Dual Functional Doxorubicin-Fe3O4 Nanotherapy Drugs

A molecular hybrid comprising AS1411 and PDGF‐BB aptamer, cholesterol, and doxorubicin for inhibiting proliferation of SW480 cells

Identification of Molecules by Spectral Imaging

Contact Info

Product

Resources

About